Inventor
KIN TSO
Inventor
US
Overview
Patents· 11 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations31%
C07DHeterocyclic compounds31%
A61KPreparations for medical, dental or toiletry purposes23%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium11%
Y02PClimate change mitigation technologies in the production or processing of goods3%
PatentTitleYear
12,503,438Compounds for the treatment of kinase-dependent disorders202512,371,428Pyridone compounds and methods of use202511,993,594IRAK inhibitors and method for making and using202411,939,317Amide compounds and method for making and using202411,827,628Compositions and methods for inhibition of the JAK pathway202311,667,611Compositions and methods for inhibition of the JAK pathway202311,542,259Compounds for the treatment of kinase-dependent disorders202311,530,194Amide compounds and method for making and using202211,492,349IRAK inhibitors and method for making and using202211,370,808Pyrazole compounds and methods for making and using the compounds202211,198,689Compositions and methods for inhibition of the JAK pathway2021Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2021–2024Patents assigned to RIGEL PHARMACEUTICALS INC (8)· patent assignee history
2021–2025Based in US· patent location history
2023–2025Patents assigned to EXELIXIS INC (3)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| RIGEL PHARMACEUTICALS INC | 8 | 2021–2024 |
| EXELIXIS INC | 3 | 2023–2025 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 11 | 2021–2025 |